A year‑end compilation reports total money raised by biopharma companies (public, private and other financings) through Dec. 24, 2025, providing a consolidated view of capital flows for the sector. The dataset highlights where investor appetite concentrated in 2025 and helps companies benchmark financing outcomes amid shifting public markets and VC activity. Readers should use the snapshot to compare segment‑level financing and to assess where cash availability will influence R&D timelines and deal activity into 2026.